Articles On Opthea (ASX:OPT)

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.8% to 7,319.9 points. Four ASX shares that have failed to follow the market higher today are...

In early afternoon trade on Tuesday, the S&P/ASX 200 Index (ASX: XJO) has given back its morning gains and is sinking. At the time of writing, the benchmark index is down 0.3% to 7,294.9 points. Four ASX shares that are not letting tha...

The Opthea Ltd (ASX: OPT) share price is soaring today, up more than 8% trading at $1.37 at the time of writing. The clinical stage biopharmaceutical company is focused on developing therapies to treat progressive retinal diseases. Below,...

Immutep (ASX:IMM) and Opthea (ASX:OPT) both received the blessing of the FDA for their clinical trial ambitions this morning, with Immutep winning approval to start a clinical trial and Opthea winning Fast Track Designation.   Opthea gets F...

Opthea (ASX:OPT) has announced that the US FDA has granted Fast Track designation for its OPT-302 in combination with anti-VEGFA therapy for the treatment of patients with neovascular age-related macular degeneration.

Didi ban and Kaseya ransom Wall Street was closed on Monday due to the extended Independence Day long weekend. Chinese regulators ordered app stores in China to block ride-hailing Didi app from being downloaded, just less than a week after...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and trading lower. At the time of writing, the benchmark index is down 0.3% to 7,363.5 points. Four ASX shares that are not letting that hold them back are liste...

The best performer on the All Ordinaries on Thursday has been the Opthea Ltd (ASX: OPT) share price. In morning trade, the biotechnology company’s shares are up 12% to $1.58. Why is the Opthea share price rocketing higher? Investors have b...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Goldman Sachs hosted its 4th small/mid-cap healthcare forum this week. This included 13 Australian and New Zealand healthcare companies across a diverse range of specialties. Here are the ASX healthcare shares that Goldman picked as a buy....

Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has been granted a meeting with the US Food and Drug Administration to discuss the planned development pathway for its lead drug Presendin in the treatment of disorders...

Source: PHICHCHA, Shutterstock Small-cap stocks can be surprising investments as they can offer high revenues within a short span of time. These stocks might not be the most expensive ones. However, they can gain significant value over tim...

Pitt Street Research has initiated coverage on Melbourne biotech company Exopharm (ASX:EX1), declaring it is currently significantly undervalued and could be re-rated by the market. In a 29-page research report, Pitt Street Research lauded...

Source:Ratanapon Srisuneton, Shutterstock Summary Opthea gets an iPSP waiver from the FDA for its lead product candidate to treat wet AMD. Paradigm and bene pharmaChem set to collaborate for the development of iPPS and other formulati...

In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1.6% to 6,845.9 points. Four ASX shares that are climbing more than most today are liste...

The Opthea Ltd (ASX: OPT) share price is up 8.39% to $1.55 this morning. The rise comes after receiving an initial Pediatric Study Plan (iPSP) waiver from the US Food and Drug Administration (FDA) for OPT-302.  Opthea is committed to impro...

Wall Street pulls back as tech stocks retreat All the major US indices fell last night. Dow Jones was down slightly by 0.3%, while S&P 500 and NASDAQ fell by 0.32% and 0.11% respectively. Tech stocks like Apple, Microsoft, Amazon, and F...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Emerging Australian biotechnology company Opthea (ASX:OPT) has announced that the first patient has been treated in the phase three pivotal clinical program of its first-in-class VEGF-C/D ‘trap’ inhibitor.

Source: Zolnierek, Shutterstock Summary Opthea Limited announced the commencement of dosing in the pivotal Phase 3 clinical trial of OPT-302. The biopharmaceutical company would evaluate primary and secondary endpoints in the Phase 3...

Opthea (ASX:OPT) says it has finalised the protocol study designs and key start-up activities in readiness for the initiation of the phase three ShORe and COAST pivotal clinical trials of OPT-302 in wet age-related macular degenerat...

Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has welcomed seasoned drug development expert Dr Megan Baldwin to the board as an independent non-executive director, effective today. Dr Baldwin has more than two decad...

Megan Baldwin, a biotech executive well-known as CEO of Opthea (ASX:OPT), has come onboard another ASX biotech stock. Dr Baldwin ... Read More The post Megan Baldwin just joined the board of this ASX biotech stock appeared first on Stockhea...

Invex Therapeutics (ASX: IXC) is aiming to hit some significant milestones in 2021 in its bid to use a diabetic drug for a neurological condition in desperate need for treatment. The biopharmaceutical company is focused on repurposing the d...

Biopharmaceutical company Opthea is poised to undertake two phase-3 trials for its treatment to improve vision for those affected by macular degeneration -OPT-302 designed to achieve broader suppression of wAMD-Trial data anticipated in the...

During October the ASX200 outperformed most developed markets peers, with the financial and technology sectors leading the way. -The ASX200 climbed 1.9% during October-Banks rose and technology outperformed-JPMorgan sees AUD/USD at 68c by y...

More than a dozen ASX stocks, mostly in healthcare, are dual-listed in America. Another ASX stock is about to join ... Read More The post ASX stocks in America: Opthea’s about to join the ranks but who’s there already? appeared first on Sto...

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a strong gain. At the time of writing, the benchmark index is up 1% to 6,240.2 points. Four shares that have failed to follow the market higher...

Australian clinical-stage biopharmaceutical company Opthea (ASX:OPT) has launched its initial public offering of American Depositary Shares.

One side of the Australian share market which I think is a great place to look for investment ideas is the mid cap space. I’m a big fan of mid cap shares as they offer stronger potential returns than large caps, but arguably carry less ris...

Summary ASX and TSX listed Company Orocobre Limited disclosed the successful completion of its SPP by raising almost A$43 million, which is A$13 million above from its original target. ASX 300 listed PointsBet Holdings Limited disclosed...

Summary Opthea Limited disclosed that the Company had filed a registration statement for proposed Initial Public Offering (IPO) in the US. The Company also aims to list the American Depositary Shares (ADSs) on the Nasdaq Global Market u...

25 Sep 2020 - Biopharmaceutical company Opthea (ASX:OPT) has revealed plans to list American depositary receipts on the Nasdaq index.

I continue to believe that the healthcare sector is a great place to invest with a long term view. This is due to favourable industry tailwinds which look set to support demand for healthcare services for a long time to come. While I think...

Today we will look at why we like Opthea Limited (ASX OPT). Opthea Limited is an emerging healthcare company that specialises in developing novel treatments for chronic eye diseases such as age-related macular degeneration. Macular degenera...

With biotechnology in focus in 2020, Race Oncology is attracting investor interest. -2020 booming times for (some) biotechnology stocks-Race Oncology aiming to revive 1980’s Acute Myeloid Leukemia (AML) treatment-Bisantrene clinical trials...

The Opthea Ltd (ASX: OPT) share price bounced up 5% then crashed this morning after the biotech company announced plans for a listing in the United States. At the time of writing, Opthea shares had dropped back down to $2.52 after opening...

The Opthea Ltd (ASX: OPT) share price is surging higher today. This follows the release of an update on its meetings with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). At the time of writing the clini...

I think that every portfolio should have some exposure to the healthcare industry, including 1 or 2 small-caps that make up less than 5% of the total portfolio’s value. Emerging ASX biotech companies such as Opthea Ltd (ASX: OPT) and Polyn...

Long-term shareholders of emerging ASX healthcare company Opthea Ltd (ASX: OPT) have endured a volatile 12 months. A little under a year ago, the Opthea share price was trading at a 52-week low of just $0.735. Then, in the space of a month...

Like many companies, junior ASX healthcare company Medical Developments International Limited (ASX: MVP) has had a volatile 2020. After soaring to an all-time high of $11.78 in February, the Medical Developments share price was savaged in...

The Opthea Limited (ASX: OPT) share price surged more than 20% during trade today, following the company’s recent announcement about its data being presented at an upcoming industry conference.  What did Opthea announce? Earlier today, Opt...

The S&P/ASX 200 (ASX: XJO) is down over 10% compared to this time a year ago. Individual share performances have varied in the wake of the coronavirus pandemic with some surging and others wilting.  The shift to eCommerce hastened by t...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The market...

Australia’s top brokers have been busy adjusting their estimates and recommendations again, leading to the release of a large number of broker notes this week. Three broker buy ratings that have caught my eye are summarised below. Here’s w...